K Number
K232295
Device Name
LAA Exclusion System
Manufacturer
Date Cleared
2023-08-30

(29 days)

Product Code
Regulation Number
878.4300
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
The LAA Exclusion System is indicated for the exclusion of the heart's left atrial appendage, performed under direct visualization and in conjunction with other cardiac surgical procedures. Direct visualization, in this context, requires that the surgeon is able to see the heart directly, with or without assistance from a camera, endoscope, etc., or any other appropriate viewing technology.
Device Description
The LAA Exclusion System consists of a single use, sterile, self-closing, implantable Clip preloaded on a single use delivery system. When closed, the implant applies pressure to ensure exclusion of the left atrial appendage (LAA). Once the clip is deployed, it remains as a permanent implant. The implantable clip is available in lengths of 35mm, 40mm, 45mm to accommodate different sizes of LAA. The LAA Selection Guide is a sterile, single use, disposable surgical accessory device to assist the physician in selecting the appropriately sized clip implant for each individual patient.
More Information

Not Found

No
The summary describes a mechanical device (clip and delivery system) and a sizing guide. There is no mention of AI/ML terms, image processing, or data sets for training/testing algorithms. The performance studies focus on mechanical and functional aspects of the device.

Yes
The device is described as an implantable clip used to exclude the heart's left atrial appendage, indicating a direct therapeutic intervention to treat a medical condition.

No

The device is an implantable system designed to exclude the left atrial appendage, which is a treatment, not a diagnostic, procedure. While a selection guide assists in sizing, it doesn't diagnose a condition.

No

The device description explicitly states that the system consists of a physical, implantable clip and a delivery system, which are hardware components.

Based on the provided information, this device is not an IVD (In Vitro Diagnostic).

Here's why:

  • Intended Use: The intended use is for the "exclusion of the heart's left atrial appendage, performed under direct visualization and in conjunction with other cardiac surgical procedures." This describes a surgical intervention performed directly on the patient's body.
  • Device Description: The device is an "implantable Clip preloaded on a single use delivery system." This is a physical device designed to be implanted within the body.
  • Lack of In Vitro Activity: IVD devices are used to examine specimens (like blood, urine, tissue) outside of the body to provide information about a person's health. This device does not interact with specimens in this way.

The device is a surgical implant used for a therapeutic purpose (excluding the LAA), not for diagnostic testing of samples outside the body.

N/A

Intended Use / Indications for Use

The LAA Exclusion System is indicated for the exclusion of the heart's left atrial appendage, performed under direct visualization and in conjunction with other cardiac surgical procedures.

Direct visualization, in this context, requires that the surgeon is able to see the heart directly, with or without assistance from a camera, endoscope, etc., or any other appropriate viewing technology.

Product codes

PZX

Device Description

The LAA Exclusion System consists of a single use, sterile, self-closing, implantable Clip preloaded on a single use delivery system. When closed, the implant applies pressure to ensure exclusion of the left atrial appendage (LAA). Once the clip is deployed, it remains as a permanent implant. The implantable clip is available in lengths of 35mm, 40mm, 45mm to accommodate different sizes of LAA. The LAA Selection Guide is a sterile, single use, disposable surgical accessory device to assist the physician in selecting the appropriately sized clip implant for each individual patient.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

heart's left atrial appendage

Indicated Patient Age Range

Not Found

Intended User / Care Setting

surgeon

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies

Design verification testing was performed to ensure that the modified LAA Exclusion System continues to meet its performance specifications. The following tests were conducted to demonstrate equivalence to the predicate device: Bent Shaft Functional Check, Trigger Actuation Force, Deployment/Recapture, Clip Orientation, One Pin Mis-Capture, Recapture Indicator, Implant Tip Opening, Implant Root Opening, Implant Deployment Force, Implant Recapture Force, Implant Retention Strength, Implant Forced Pull-Off, Max Dose Sterilization. All pre-determined acceptance criteria were met.

Key Metrics

Not Found

Predicate Device(s)

K220305

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 878.4300 Implantable clip.

(a)
Identification. An implantable clip is a clip-like device intended to connect internal tissues to aid healing. It is not absorbable.(b)
Classification. Class II.

0

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo features the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.

August 30, 2023

Syntheon, LLC Toygar Unal Director of Quality 13755 SW 119 Avenue Miami, Florida 33186

Re: K232295

Trade/Device Name: LAA Exclusion System Regulation Number: 21 CFR 878.4300 Regulation Name: Implantable clip Regulatory Class: Class II Product Code: PZX Dated: July 26, 2023 Received: August 1, 2023

Dear Toygar Unal:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's

1

requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Katherine N. Trivedi -S

for Rachel Neubrander Assistant Director DHT2B: Division of Circulatory Support, Structural and Vascular Devices OHT2: Office of Cardiovascular Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

2

Indications for Use

510(k) Number (if known) K232295

Device Name LAA Exclusion System

Indications for Use (Describe)

The LAA Exclusion System is indicated for the exclusion of the heart's left atrial appendage, performed under direct visualization and in conjunction with other cardiac surgical procedures.

Direct visualization, in this context, requires that the surgeon is able to see the heart directly, with or without assistance from a camera, endoscope, etc., or any other appropriate viewing technology.

Type of Use (Select one or both, as applicable)
☑ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C)☑ Prescription Use (Part 21 CFR 801 Subpart D)☐ Over-The-Counter Use (21 CFR 801 Subpart C)
☑ Prescription Use (Part 21 CFR 801 Subpart D)☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

3

510(k) Summary

Date Summary Prepared: July 26, 2023

Applicant:

Syntheon 13755 SW 119 Avenue Miami, FL 33186

Contact Person:

Toygar Unal Director of Quality Syntheon 13755 SW 119 Avenue Miami, FL 33186 Telephone: 1-973-997-8532 Email: tunal@syntheon.com

Trade Name:

LAA Exclusion System

Device Common or Classification Name:

Left Atrial Appendage Clip, Implantable

Review Panel:

Cardiovascular

Product Class:

Class II

Product Code:

PZX

Predicate Device:

K220305, Syntheon LAA Exclusion System

Device Description:

The LAA Exclusion System consists of a single use, sterile, self-closing, implantable Clip preloaded on a single use delivery system. When closed, the implant applies pressure to ensure exclusion of the left atrial appendage (LAA). Once the clip is deployed, it remains as a permanent implant. The implantable clip is available in lengths of 35mm, 40mm, 45mm to accommodate different sizes of LAA. The LAA Selection Guide is a sterile, single use, disposable surgical accessory device to assist the physician in selecting the appropriately sized clip implant for each individual patient.

4

Indications for Use:

The LAA Exclusion System is indicated for the exclusion of the heart's left atrial appendage, performed under direct visualization and in conjunction with other cardiac surgical procedures.

Direct visualization, in this context, requires that the surgeon is able to see the heart directly, with or without assistance from a camera, endoscope, etc., or any other appropriate viewing technology.

Comparison of Technological Characteristics with the Predicate Device (LAA Exclusion System, K220305):

The modifications to the LAA Exclusion System include minor changes to the following, dimensional and shape changes to the release wire, an increase in the recapture force specification, addition of a new specification around recapture without depressing the release trigger, and an update to the IFU instructions for use to instruct the user to depress the release trigger during recapture. A comparison of the technological characteristics of the subject device is summarized in Table 1.

Table 1: Comparison of Technological Characteristics
CharacteristicSubject Device
LAA Exclusion SystemPredicate Device
LAA Exclusion System
(K220305)Rationale for
Substantial
Equivalence
Indications for
UseThe LAA Exclusion System is
indicated for the exclusion of
the heart's left atrial
appendage, performed under
direct visualization and in
conjunction with other cardiac
surgical procedures.
Direct visualization, in this
context, requires that the
surgeon is able to see the heart
directly, with or without
assistance from a camera,
endoscope, etc., or other
appropriate viewing
technologies.The LAA Exclusion System is
indicated for the exclusion of
the heart's left atrial
appendage, performed under
direct visualization and in
conjunction with other cardiac
surgical procedures.
Direct visualization, in this
context, requires that the
surgeon is able to see the
heart directly, with or without
assistance from a camera,
endoscope, etc., or other
appropriate viewing
technologies.Identical
Product CodePZXPZXIdentical
Regulation No.21CFR878.430021CFR878.4300Identical
ClassificationClass IIClass IIIdentical
ComponentsImplantable clip and disposable
clip applier (delivery system)Implantable clip and
disposable clip applier
(delivery system)Identical
Principle of
OperationThe clip is comprised of two
springs biasing two bars
together with constant force for
the exclusion of the left atrial
appendage.The clip is comprised of two
springs biasing two bars
together with constant force
for the exclusion of the left
atrial appendage.Identical
Clip SizeClip Size LAA Size Range:Clip Size LAA Size Range:Identical

5

Table 1: Comparison of Technological Characteristics
CharacteristicSubject Device
LAA Exclusion SystemPredicate Device
LAA Exclusion System
(K220305)Rationale for
Substantial
Equivalence
35 mm: 39-35 mm 40 mm: 34-40 mm 45 mm: 39-45 mm 50 mm: 44-50 mm35 mm: 39-35 mm 40 mm: 34-40 mm 45 mm: 39-45 mm 50 mm: 44-50 mm
Clip OpeningTip opens to a minimum of 12 mm at the distal end.Tip opens to a minimum of 12 mm at the distal end.Identical
BiocompatibilityMaterials have been assessed based on ISO 10993 and are commonly employed in tissue contacting devices.Materials have been assessed based on ISO 10993 and are commonly employed in tissue contacting devices.Identical
Single Use OnlyYesYesIdentical
SterilizationGamma RadiationGamma RadiationIdentical
PyrogenicityNonpyrogenicNonpyrogenicIdentical
MRI CompatibilityMR ConditionalMR ConditionalIdentical

Performance Data:

Design verification testing was performed to ensure that the modified LAA Exclusion System continues to meet its performance specifications. The following tests were conducted to demonstrate equivalence to the predicate device.

  • Bent Shaft Functional Check
  • Trigger Actuation Force
  • . Deployment/Recapture
  • . Clip Orientation
  • One Pin Mis-Capture ●
  • Recapture Indicator
  • Implant Tip Opening
  • Implant Root Opening
  • Implant Deployment Force
  • Implant Recapture Force
  • Implant Retention Strength
  • Implant Forced Pull-Off
  • . Max Dose Sterilization

All pre-determined acceptance criteria were met. The data demonstrate that the modified LAA Exclusion System is substantially equivalent to the predicate device.

Conclusion:

6

Review of the design verification test data as well as comparison of the indications for use, operating principle, technological characteristics, sterility, and biocompatibility demonstrate that the modified LAA Exclusion System is substantially equivalent to the predicate LAA Exclusion System cleared under K220305.